Quality of life (QoL) researches in sarcoidosis have hardly received an appropriate attention. The most important explanation is the lack of disease-specific QoL questionnaire. Since May 2003 Sarcoidosis Health Questionnaire (SHQ) has been introduced. This is the first disease-specific questionnaire. The purpose of this study was to evaluate the QoL in sarcoidosis patients, regarding the treatment using SHQ .
197 biopsy positive sarcoidosis patients were analyzed. Considering the treatment patients were divided into three groups: I- 42 patients without therapy, II-115 patients treated with morbostatic doses of prednisolone (5-15mg/daily), III-40 patients treated with methotrexate (10-15 mg orally / weekly). The groups were similar regarding male/female ratio (1:2.5) and the mean age. Patients with comorbidity were excluded. SHQ scores were calculated by PC software, with author’s permission.
Mean SHQ scores were the lowest in- the III group (daily 4.08±0.60, physical 4.13±0.89, emotional 3.92±0.63, total 4.04±0.5). All SHQ scores showed statistically significant differences between groups (p<0.01, ANOVA). Statistically significant correlation between all SHQ scores and therapy groups (p<0.01, Spearman’s rho coefficient) was found as well.
The lowest SHQ scores were recorded in sarcoidosis patients with the chronic form, requiring cytotoxic treatment. SHQ is reliable instrument in evaluating health problems in broad spectrum of sarcoidosis patients: from those with modest disease requiring no treatment at all, to those with the most serious form of disease requiring cytotoxic treatment.
SHQ is an excellent instrument for assessment of QoL in sarcoidosis patients that is highly recommended for routine clinical practice.
V. Vucinic, None.